Literature DB >> 22456231

Novel intrapleural therapies for malignant diseases.

Andrew R Haas1, Daniel H Sterman.   

Abstract

Pleural malignancies, either primary or metastatic, are common and problematic clinical issues in thoracic oncology and pulmonary medicine. Malignant pleural mesothelioma and metastatic pleural effusions often present late in the course of a disease and have a dramatic impact on the patient's quality of life and survival. Novel approaches to manage mesothelioma and malignant pleural effusions are desperately needed and the pleural space provides a unique platform as an easily accessible body cavity for developing and assessing these treatments and their responses. In this review, we discuss the unique intrapleural chemotherapeutic, immunotherapeutic and genetic treatments that have been investigated, as well as those under current clinical development. While responses have been demonstrated to variable degrees with all these approaches, an integrated multimodality approach incorporating these methods with other anti-neoplastic interventions ultimately will ensure the best responses and patient outcomes.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22456231     DOI: 10.1159/000337060

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  3 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion.

Authors:  Qian Li; Dong-Mei Yuan; Li-Hong Ma; Chen-Hui Ma; Ya-Fang Liu; Tang-Feng Lv; Yong Song
Journal:  Tumour Biol       Date:  2016-10-22

3.  Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: a case report.

Authors:  Qihua Gu; Chengping Hu; Jingjing Qu
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.